<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2783">
  <stage>Registered</stage>
  <submitdate>19/05/2010</submitdate>
  <approvaldate>19/05/2010</approvaldate>
  <nctid>NCT01129661</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers</studytitle>
    <scientifictitle>An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CSLCT-HDL-09-63</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - CSL112 (reconstituted HDL)
Other interventions - normal saline (0.9%)

Placebo Comparator: normal saline (0.9%) - 

Experimental: CSL112 - 


Other interventions: CSL112 (reconstituted HDL)
Single escalating intravenous doses of CSL112

Other interventions: normal saline (0.9%)
Single intravenous dose of normal saline (0.9%)

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability as measured by the frequency of drug-related clinical adverse events.</outcome>
      <timepoint>Up to 14 days after infusion of CSL112</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety and tolerability as measured by liver function tests.</outcome>
      <timepoint>Up to 14 days after infusion of CSL112</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of lipoprotein. - Plasma levels of lipoprotein.</outcome>
      <timepoint>Up to 10 days after infusion of CSL112</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy males and females aged 18 years to less than 55 years

          -  Body weigh 45 kg or greater</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>54</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Evidence of a clinically significant medical condition, disorder or disease

          -  Evidence of clinically relevant abnormal laboratory test result

          -  Evidence of history of alcohol or substance abuse</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>57</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>CMAX - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>CSL Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the safety and tolerability of escalating doses of
      CSL112 after single intravenous infusions in healthy volunteers and to measure the
      pharmacokinetics of CSL112 after single intravenous infusions in healthy volunteers.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01129661</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>